1. Adverse events associated with sodium glucose co-transporter 2 inhibitors: an overview of quantitative systematic reviews. (January 2021) Authors: Pelletier, Ryan; Ng, Kelvin; Alkabbani, Wajd; Labib, Youssef; Mourad, Nicolas; Gamble, John-Michael Journal: Therapeutic advances in drug safety Issue: Volume 12(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Assessing the risk of venous thromboembolism (VTE) in ambulatory patients with cancer: Rationale and implementation of a pharmacist-led VTE risk assessment program in an ambulatory cancer centre. (June 2021) Authors: Pelletier, Ryan Journal: Journal of oncology pharmacy practice Issue: Volume 27:Number 4(2021) Page Start: 911 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Sodium/Glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis: An Example of Complementary Evidence for Rare Adverse Events. Issue 8 (6th March 2021) Authors: Alkabbani, Wajd; Pelletier, Ryan; Gamble, John-Michael Journal: American journal of epidemiology Issue: Volume 190:Issue 8(2021) Page Start: 1572 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. The association of sodium‐glucose cotransporter 2 inhibitors with cancer: An overview of quantitative systematic reviews. Issue 3 (20th May 2020) Authors: Pelletier, Ryan; Ng, Kelvin; Alkabbani, Wajd; Labib, Youssef; Mourad, Nicolas; Gamble, John‐Michael Journal: Endocrinology, diabetes & metabolism Issue: Volume 3:Issue 3(2020) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗